Soleno Therapeutics
(NASDAQ) SLNO
This security has been delisted. This page is retained for historical reference.
SLNO News
SLNO: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowSLNO Financials
Key Financial Metrics (TTM)
Gross Margin
99%
Operating Margin
31%
Net Income Margin
34%
Return on Equity
23%
Return on Capital
16%
Return on Assets
16%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$187.71M
Operating Income
$14.95M
EBITDA
$28.38M
Operating Cash Flow
$46.80M
Capital Expenditure
$73.00K
Free Cash Flow
$46.73M
Cash & ST Invst.
$305.47M
Total Debt
$2.69M
Soleno Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$94.60M
N/A
Gross Profit
$93.41M
N/A
Gross Margin
98.73%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
115
N/A
Net Income
$31.38M
+171.7%
EBITDA
$32.28M
+177.0%
Quarterly Fundamentals
Net Cash
$251.19M
+5.9%
Accounts Receivable
$47.14M
N/A
Inventory
$17.31M
N/A
Long Term Debt
$3.24M
-93.8%
Short Term Debt
$1.16M
+94.8%
Return on Assets
15.79%
N/A
Return on Invested Capital
15.95%
N/A
Free Cash Flow
$25.94M
+179.2%
Operating Cash Flow
$25.98M
+179.3%